{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:32:21Z","timestamp":1795231941460,"version":"4.10.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Assistance Publique - H\u00f4pitaux de Paris; Sorbonne University"},{"name":"French Ministry of Solidarity and Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the <jats:italic>LMNA<\/jats:italic> gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins), is to provide health professionals with a guide to optimal management and care of patients with FPLD2, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), is available on the French Health Authority website (in French). Dunnigan syndrome is characterized by a partial atrophy of the subcutaneous adipose tissue and by an insulin resistance syndrome, associated with a risk of metabolic, cardiovascular and muscular complications. Its prevalence, assessed at 1\/100.000 in Europe, is probably considerably underestimated. Thorough clinical examination is key to diagnosis. Biochemical testing frequently shows hyperinsulinemia, abnormal glucose tolerance and hypertriglyceridemia. Elevated hepatic transaminases (hepatic steatosis) and creatine phosphokinase, and hyperandrogenism in women, are common. Molecular analysis of the <jats:italic>LMNA<\/jats:italic> gene confirms diagnosis and allows for family investigations. Regular screening and multidisciplinary monitoring of the associated complications are necessary. Diabetes frequently develops from puberty onwards. Hypertriglyceridemia may lead to acute pancreatitis. Early atherosclerosis and cardiomyopathy should be monitored. In women, polycystic ovary syndrome is common. Overall, the management of patients with Dunnigan syndrome requires the collaboration of several health care providers. The attending physician, in conjunction with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. The various elements of this PNDS are described to provide such a support.<\/jats:p>","DOI":"10.1186\/s13023-022-02308-7","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T16:05:52Z","timestamp":1650384352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)"],"prefix":"10.1186","volume":"17","author":[{"given":"H.","family":"Mosbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-4782","authenticated-orcid":false,"given":"B.","family":"Donadille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Janmaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Atlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Badens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"B\u00e9liard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ben Yaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bismuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chaouat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Charriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Christin-Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Kerdanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Disse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"F\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lascols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nob\u00e9court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poujol-Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tauveron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Treboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vermot-Desroches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"J\u00e9ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"2308_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DMSO.S130810","volume":"10","author":"E Chiquette","year":"2017","unstructured":"Chiquette E, Oral EA, Garg A, Ara\u00fajo-Vilar D, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabet Metab Syndr Obes Targets Ther. 2017;10:375\u201383.","journal-title":"Diabet Metab Syndr Obes Targets Ther"},{"issue":"2","key":"2308_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/db19-0447","volume":"69","author":"C Gonzaga-Jauregui","year":"2020","unstructured":"Gonzaga-Jauregui C, Ge W, Staples J, Van Hout C, Yadav A, et al. Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes. 2020;69(2):249\u201358.","journal-title":"Diabetes"},{"issue":"4","key":"2308_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1210\/jc.2018-01922","volume":"104","author":"N Patni","year":"2019","unstructured":"Patni N, Li X, Adams-Huet B, Vasandani C, Gomez-Diaz RA, Garg A. Regional body fat changes and metabolic complications in children with dunnigan lipodystrophy-causing LMNA variants. J Clin Endocrinol Metab. 2019;104(4):1099\u2013108.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2308_CR4","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2308_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","volume":"86","author":"N Ajluni","year":"2017","unstructured":"Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol. 2017;86(5):698\u2013707.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2308_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ando.2019.10.003","volume":"81","author":"C Sollier","year":"2020","unstructured":"Sollier C, Vatier C, Capel E, Lascols O, Auclair M, Janmaat S, et al. Lipodystrophic syndromes: from diagnosis to treatment. Ann Endocrinol. 2020;81(1):51\u201360.","journal-title":"Ann Endocrinol"},{"issue":"4","key":"2308_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","volume":"45","author":"I Hussain","year":"2016","unstructured":"Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin N Am. 2016;45(4):783\u201397.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"1","key":"2308_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13023-020-01364-1","volume":"15","author":"D Ara\u00fajo-Vilar","year":"2020","unstructured":"Ara\u00fajo-Vilar D, Fern\u00e1ndez-Pombo A, Rodr\u00edguez-Carnero G, et al. LipoDDx: A mobile application for identification of rare lipodystrophy syndromes. Orphanet J Rare Dis. 2020;15(1):81.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2308_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ando.2012.04.010","volume":"73","author":"MC Vantyghem","year":"2012","unstructured":"Vantyghem MC, Balavoine AS, Douillard C, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol. 2012;73(3):170\u201389.","journal-title":"Ann Endocrinol"},{"issue":"8","key":"2308_CR10","doi-asserted-by":"publisher","first-page":"E1410","DOI":"10.1210\/jc.2013-1297","volume":"98","author":"H Ji","year":"2013","unstructured":"Ji H, Weatherall P, Adams-Huet B, Garg A. Increased skeletal muscle volume in women with familial partial lipodystrophy, dunnigan variety. J Clin Endocrinol Metab. 2013;98(8):E1410\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2308_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","volume":"45","author":"M Kwapich","year":"2019","unstructured":"Kwapich M, Lacroix D, Espiard S, et al. Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype\u2013genotype correlation. Diabetes Metab. 2019;45(4):382\u20139.","journal-title":"Diabetes Metab"},{"key":"2308_CR12","first-page":"66","volume":"6","author":"G Treiber","year":"2021","unstructured":"Treiber G, Flaus-Furmaniuk A, Guilleux A, et al. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. Eur J Endocrinol. 2021;6:66.","journal-title":"Eur J Endocrinol."},{"issue":"23","key":"2308_CR13","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","volume":"37","author":"YM Pinto","year":"2016","unstructured":"Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850\u20138.","journal-title":"Eur Heart J"},{"issue":"9","key":"2308_CR14","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1161\/ATVBAHA.113.301933","volume":"33","author":"G Bidault","year":"2013","unstructured":"Bidault G, Garcia M, Vantyghem MC, et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33(9):2162\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"2308_CR15","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.2337\/diabetes.49.11.1958","volume":"49","author":"C Vigouroux","year":"2000","unstructured":"Vigouroux C, Magr\u00e9 J, Vantyghem MC, et al. Lamin A\/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes. 2000;49(11):1958\u201362.","journal-title":"Diabetes"},{"issue":"10","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","volume":"100","author":"A L\u00fcdtke","year":"2005","unstructured":"L\u00fcdtke A, Genschel J, Brabant G, et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol. 2005;100(10):2218\u201324.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2308_CR17","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","volume":"105","author":"C Vasandani","year":"2020","unstructured":"Vasandani C, Li X, Sekizkardes H, Adams-Huet B, Brown RJ, Garg A. Diagnostic value of anthropometric measurements for familial partial lipodystrophy, dunnigan variety. J Clin Endocrinol Metab. 2020;105(7):2132\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2308_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","volume":"9","author":"S Shackleton","year":"2000","unstructured":"Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy. Hum Mol Genet. 2000;9(1):109\u201312.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2308_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med."},{"issue":"2","key":"2308_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/path.2999","volume":"226","author":"HJ Worman","year":"2012","unstructured":"Worman HJ. Nuclear lamins and laminopathies. J Pathol. 2012;226(2):316\u201325.","journal-title":"J Pathol"},{"issue":"5","key":"2308_CR21","doi-asserted-by":"publisher","first-page":"E856","DOI":"10.1210\/jc.2010-2234","volume":"96","author":"C Le Dour","year":"2011","unstructured":"Le Dour C, Schneebeli S, Bakiri F, et al. A homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A. J Clin Endocrinol Metab. 2011;96(5):E856\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2308_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ahj.2014.12.021","volume":"169","author":"P Andre","year":"2015","unstructured":"Andre P, Schneebeli S, Vigouroux C, Lascols O, Schaaf M, Chevalier P. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. Am Heart J. 2015;169(4):587\u201393.","journal-title":"Am Heart J"},{"issue":"6","key":"2308_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jmedgenet-2016-104437","volume":"54","author":"I Jeru","year":"2017","unstructured":"Jeru I, Vatier C, Vantyghem MC, Lascols O, Vigouroux C. LMNA-associated partial lipodystrophy: anticipation of metabolic complications. J Med Genet. 2017;54(6):413\u20136.","journal-title":"J Med Genet"},{"issue":"1","key":"2308_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/01.ATV.0000047460.27435.B8","volume":"23","author":"RA Hegele","year":"2003","unstructured":"Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A\/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol. 2003;23(1):111\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2308_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","volume":"46","author":"M Lightbourne","year":"2017","unstructured":"Lightbourne M, Brown RJ. Genetics of Lipodystrophy. Endocrinol Metab Clin N Am. 2017;46(2):539\u201354.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2308_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12887-016-0581-2","volume":"16","author":"P Krawiec","year":"2016","unstructured":"Krawiec P, Me\u0142ges B, Pac-Kozuchowska E, Mroczkowska-Juchkiewicz A, Czerska K. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl. BMC Pediatr. 2016;16:38.","journal-title":"BMC Pediatr"},{"issue":"6","key":"2308_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1053\/j.gastro.2018.03.026","volume":"154","author":"GF Brady","year":"2018","unstructured":"Brady GF, Kwan R, Bragazzi Cunha J, Elenbaas JS, Omary MB. Lamins and Lamin-associated proteins in gastrointestinal health and disease. Gastroenterology. 2018;154(6):1602-1619.e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"2308_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cgh.2018.08.069","volume":"17","author":"F Bazerbachi","year":"2019","unstructured":"Bazerbachi F, Haffar S, Wang Z, et al. Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals. Clin Gastroenterol Hepatol. 2019;17(1):54-64.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2308_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000495767","volume":"26","author":"A Ribeiro","year":"2019","unstructured":"Ribeiro A, Brandao JR, Cleto E, et al. Fatty liver and autoimmune hepatitis: two forms of liver involvement in lipodystrophies. GE Port J Gastroenterol. 2019;26(5):362\u20139.","journal-title":"GE Port J Gastroenterol"},{"issue":"1","key":"2308_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/19491034.2018.1456217","volume":"9","author":"C Vigouroux","year":"2018","unstructured":"Vigouroux C, Gu\u00e9nantin AC, Vatier C, et al. Lipodystrophic syndromes due to lmna mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018;9(1):251\u201364.","journal-title":"Nucleus"},{"issue":"4","key":"2308_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","volume":"140","author":"K Wahbi","year":"2019","unstructured":"Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140(4):293\u2013302.","journal-title":"Circulation"},{"issue":"2","key":"2308_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabet.2020.08.002","volume":"47","author":"P Valensi","year":"2021","unstructured":"Valensi P, Henry P, Boccara F, et al. Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. Diabetes Metab. 2021;47(2):101\u201385.","journal-title":"Diabetes Metab"},{"issue":"6","key":"2308_CR33","doi-asserted-by":"publisher","first-page":"e001603","DOI":"10.1161\/CIRCGENETICS.116.001603","volume":"10","author":"S Nishiuchi","year":"2017","unstructured":"Nishiuchi S, Makiyama T, Aiba T, et al. Gene-based risk stratification for cardiac disorders in LMNA mutation carriers. Circ Cardiovasc Genet. 2017;10(6):e001603.","journal-title":"Circ Cardiovasc Genet"},{"issue":"7","key":"2308_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1503\/cmaj.070135","volume":"177","author":"RA Hegele","year":"2007","unstructured":"Hegele RA, Al-Attar SA, Rutt BK. Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. CMAJ. 2007;177(7):743\u20135.","journal-title":"CMAJ"},{"issue":"4","key":"2308_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11325-009-0261-7","volume":"13","author":"K Patel","year":"2009","unstructured":"Patel K, Roseman D, Burbank H, Attarian H. Obstructive sleep apnea in familial partial lipodystrophy type 2 with atypical skin findings and vascular disease. Sleep Breath. 2009;13(4):425\u20137.","journal-title":"Sleep Breath"},{"issue":"5","key":"2308_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ando.2012.09.001","volume":"73","author":"P Gourdy","year":"2012","unstructured":"Gourdy P, Bachelot A, Catteau-Jonard S, et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol. 2012;73(5):469\u201387.","journal-title":"Ann Endocrinol"},{"issue":"1","key":"2308_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/19491034.2018.1509659","volume":"9","author":"A Gambineri","year":"2018","unstructured":"Gambineri A, Zanotti L. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects. Nucleus. 2018;9(1):392\u20137.","journal-title":"Nucleus"},{"issue":"6","key":"2308_CR38","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1210\/jc.2007-2521","volume":"93","author":"MC Vantyghem","year":"2008","unstructured":"Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, et al. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J Clin Endocrinol Metab. 2008;93(6):2223\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2308_CR39","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1210\/jc.2003-031658","volume":"89","author":"MC Vantyghem","year":"2004","unstructured":"Vantyghem MC, Pigny P, Maurage CA, Rouaix-Emery N, Stojkovic T, Cuisset JM, et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab. 2004;89(11):5337\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2308_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/01.wnl.0000255939.73424.f8","volume":"68","author":"S Spuler","year":"2007","unstructured":"Spuler S, Kalbhenn T, Zabojszcza J, van Landeghem FKH, et al. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology. 2007;68(9):677\u201383.","journal-title":"Neurology"},{"issue":"11","key":"2308_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00256-016-2457-9","volume":"45","author":"S Teboul-Cor\u00e9","year":"2016","unstructured":"Teboul-Cor\u00e9 S, Rey-Jouvin C, Miquel A, et al. Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. Skeletal Radiol. 2016;45(11):1495\u2013506.","journal-title":"Skeletal Radiol"},{"issue":"9\u201310","key":"2308_CR42","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/jocn.14342","volume":"27","author":"C Adams","year":"2018","unstructured":"Adams C, Stears A, Savage D, Deaton C. \u00abWe\u2019re stuck with what we\u2019ve got\u00bb: the impact of lipodystrophy on body image. J Clin Nurs. 2018;27(9\u201310):1958\u201368.","journal-title":"J Clin Nurs"},{"issue":"3","key":"2308_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/03007995.2018.1533459","volume":"35","author":"C Vatier","year":"2019","unstructured":"Vatier C, Vantyghem MC, Storey C, et al. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases. Curr Med Res Opin. 2019;35(3):543\u201352.","journal-title":"Curr Med Res Opin"},{"key":"2308_CR44","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/DMSO.S206053","volume":"13","author":"C Bagias","year":"2020","unstructured":"Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial partial lipodystrophy (FPLD): recent insights. Diabetes Metab Syndr Obes. 2020;13:1531\u201344.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"2308_CR45","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/dme.13527","volume":"34","author":"F Banning","year":"2017","unstructured":"Banning F, Rottenkolber M, Freibothe I, Seissler J, Lechner A. Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist. Diabet Med. 2017;34(12):1792\u20134.","journal-title":"Diabet Med"},{"issue":"3","key":"2308_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","volume":"68","author":"C Cao","year":"2020","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020;68(3):518\u201325.","journal-title":"Endocrine"},{"issue":"12","key":"2308_CR47","first-page":"66","volume":"18","author":"B Akinci","year":"2018","unstructured":"Akinci B, Meral R, Oral EA. Update on therapeutic options in lipodystrophy. Curr Diab Rep. 2018;18(12):66.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"2308_CR48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/EJE-12-0969","volume":"168","author":"Z Ahmad","year":"2013","unstructured":"Ahmad Z, Subramanyam L, Szczepaniak L, et al. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013;168(5):771\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2308_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"7","key":"2308_CR50","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","volume":"87","author":"EA Oral","year":"2002","unstructured":"Oral EA, Ruiz E, Andewelt A, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002;87(7):3110\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2308_CR51","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1210\/jc.2016-3628","volume":"102","author":"RJ Brown","year":"2017","unstructured":"Brown RJ, Meehan CA, Cochran E, et al. Effects of metreleptin in pediatric patients with lipodystrophy. J Clin Endocrinol Metab. 2017;102(5):1511\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2308_CR52","first-page":"659","volume":"7","author":"N Ajluni","year":"2016","unstructured":"Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J Diabetes Metab. 2016;7(3):659.","journal-title":"J Diabetes Metab"},{"issue":"3","key":"2308_CR53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","volume":"64","author":"EA Oral","year":"2019","unstructured":"Oral EA, Gorden P, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500\u201311.","journal-title":"Endocrine"},{"issue":"1","key":"2308_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","volume":"59","author":"E Safar Zadeh","year":"2013","unstructured":"Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131\u20137.","journal-title":"J Hepatol"},{"issue":"5","key":"2308_CR55","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2014-4491","volume":"100","author":"T Diter-Cohen","year":"2015","unstructured":"Diter-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2308_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.pmr.2012.06.009","volume":"23","author":"AJ Skalsky","year":"2012","unstructured":"Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012;23(3):675\u201387.","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"2","key":"2308_CR57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/clp.14.13","volume":"9","author":"A Stears","year":"2014","unstructured":"Stears A, Hames C. Diagnosis and management of lipodystrophy: a practical update. Clin Lipidol. 2014;9(2):235\u201359.","journal-title":"Clin Lipidol"},{"issue":"9","key":"2308_CR58","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.bjps.2011.02.009","volume":"64","author":"DR Calderoni","year":"2011","unstructured":"Calderoni DR, Ramos TM, Rodrigues De Castro J, Kharmandayan P. Surgical management of phenotypic alterations related to the Dunnigan variety of familial partial Lipodystrophy. J Plast Reconstr Aesthetic Surg. 2011;64(9):1248\u201350.","journal-title":"J Plast Reconstr Aesthetic Surg"},{"issue":"5","key":"2308_CR59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bjps.2011.01.001","volume":"64","author":"JMF Hughes","year":"2011","unstructured":"Hughes JMF, Stephen C, Johnson AB, Wilson S. Breast augmentation in familial partial lipodystrophy: a case report. J Plast Reconstr Aesthetic Surg. 2011;64(5):66.","journal-title":"J Plast Reconstr Aesthetic Surg"},{"issue":"2","key":"2308_CR60","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12020-017-1437-8","volume":"58","author":"K Miehle","year":"2017","unstructured":"Miehle K, Stumvoll M, Fasshauer M, Hierl T. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy. Endocrine. 2017;58(2):262\u20136.","journal-title":"Endocrine"},{"issue":"3","key":"2308_CR61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/PRS.0b013e31827c6df5","volume":"131","author":"J Schuck","year":"2013","unstructured":"Schuck J, Iorio ML, Hung R, et al. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes. Plast Reconstr Surg. 2013;131(3):499\u2013506.","journal-title":"Plast Reconstr Surg"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02308-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02308-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02308-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:06:13Z","timestamp":1650481573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02308-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":61,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02308-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The National Diagnostic and Care Protocol (PNDS) for Dunnigan syndrome was developed in its first version by accredited reference and competence PRISIS centers, with methodological support from the French National Health Authority (HAS), in application of the provisions of the National Rare Diseases Plan 2005\u20132023. This new version is placed under the sole editorial responsibility of the PRISIS network.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Group statement"}},{"value":"The authors declare that they have no competing interests related to the content of the present manuscript. All participants in the drafting of the PNDS have filled out a declaration of interest, all of which are available at endocrino-sat.aphp.fr\/prisis. BD reports consulting fees\/meeting fees from Sanofi and speaking fees from Novartis, Lilly, Sanofi. BV reports consulting fees\/meeting fees from NovoNordisk, Astra-Zeneca. CVa reports consulting fees\/meeting fees from MSD, NovoNordisk, Sanofi, Aegerion, AstraZeneca; and research funding from Sanofi. CVi reports consulting fees\/meeting fees from Aegerion, Pierre Fabre Medicament, and speaking fees from NovoNordisk, Laboratoires Servier, Lilly, Ipsen Pharma, Aegerion Pharmaceuticals. EB reports consulting fees\/meeting fees from Medtronic, Abbot, Lilly, Insulet; speaking fees from NovoNordisk, Lilly, Orkyn, Abbot, DinnoSant\u00e9 and research funding from Lilly. GP reports consulting fees\/meeting fees from Lilly, NovoNordisk, Sanofi, Abbot, Medtronic, MSD, Becton Dickinson. IT reports consulting fees\/meeting fees from MSD, Pfizer SAS, Pharma Dom, Novartis, Astra Zeneca, Sanofi, Recordati Rare Disease. MA reports consulting fees\/meeting fees from Allergan, Motiva, Sebbin and research funding from PHRC, Sebbin. PR reports research funding from Roche. SCM reports consulting fees\/meeting fees from Ipsen and Ferring Pharmaceuticals. SB reports reports consulting fees\/meeting fees from Akcea Therapeutics, Sanofi, Amgen, JESFC, Univadis, Lilly. APR; DT; EN; GC; HM; KW; MC; MCV; MDK; ND; RBY; SJ; VVD did not report any conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}